Topic: targeted tumor treatment
Charles River updates its database with new tumor models for early-stage oncology research.
Researchers used the gene editing system CRISPR-Cas9 to discover a signature of resistance to BRAF inhibitors in melanoma.
California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment.
CytomX signed a biobucks deal potentially worth $1.5 billion with Amgen.
Telix has committed about $65 million in return for the exclusive right to use the antibodies to guide radioactive payloads to tumors.
A new deal answers Lilly's concerns that Ignyta wasn't holding up its end of the license disease for taladegib.